Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US00287Y1091
Ticker ABBV
Company ABBVIE
Currency $
Price
Aware Investor Index (AII) 260.0553
Recommendation STRONG BUY
P/E 32.22
ROE 86.11 %
Capitalization 141,416,660,000 $
Dividend Yield 2.98 %
P/S 5.01
AII Position 16
P/E Position 461
ROE Position 36
Capitalization Position 52
Dividend Yield Position 228
Sales 28,216,000,000 $
10-Year Average Earnings 4,388,800,000 $
Shares Outstanding 1,603,000,000
Equity 5,097,000,000 $
Dividend per Share 2.63 $
Industry Pharmaceutical
Country United States
ABBVIE Investor Relations Web Site http://www.abbvieinvestor.com







Sales:

YEAR MONTH AMOUNT
2017 12 28,216,000,000.00 $
2016 12 25,638,000,000.00 $
2015 12 22,859,000,000.00 $
2014 12 19,960,000,000.00 $
2013 12 18,790,000,000.00 $
2012 12 18,380,000,000.00 $
2011 12 17,444,000,000.00 $
2010 12 15,638,000,000.00 $
2009 12 14,214,000,000.00 $
2008 12 14,179,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 5,309,000,000.00 $
2016 12 5,953,000,000.00 $
2015 12 5,144,000,000.00 $
2014 12 1,774,000,000.00 $
2013 12 4,128,000,000.00 $
2012 12 5,275,000,000.00 $
2011 12 3,433,000,000.00 $
2010 12 4,178,000,000.00 $
2009 12 4,636,000,000.00 $
2008 12 4,058,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 5,097,000,000.00 $
2016 12 4,636,000,000.00 $
2015 12 3,945,000,000.00 $
2014 12 1,742,000,000.00 $
2013 12 4,492,000,000.00 $
2012 12 3,363,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,603,000,000
2016 12 1,631,000,000
2015 12 1,637,000,000
2014 12 1,610,000,000
2013 12 1,604,000,000
2012 12 1,577,000,000

 












Bloomberg News for ABBVIE:



Google News for ABBVIE:

Seeking Alpha - 3 hours ago
ABBV Is An Even Bigger Buy After The Midterms
Now that we have a split Congress, who seem to not be interested in any bipartisan deals, drug makers like AbbVie, Inc. (ABBV) can breathe a ...
Marea Informative (blog)
AbbVie (ABBV) Says MAVYRET Shows High Virologic Cure Rates ...
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new data for its pan-genotypic chronic ...
Top Stocks News (press release)
AbbVie Delivers A Solid Beat And Raise Quarter
AbbVie (ABBV) delivered a strong quarter producing financial results that exceeded street expectations. Revenues grew 19% and earnings per ...
Financial Mercury
Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
The trajectories for AbbVie (NYSE:ABBV) and GlaxoSmithKline (NYSE:GSK) stocks have been very different in recent years. While AbbVie ...
StreetInsider.com - 1 day ago
AbbVie: The Humira Company Is Growing Up
AbbVie's (ABBV) recent fall from grace presents a case in point. I was fortunate enough to hold a modest position in Abbott (ABT) before the ...
Seeking Alpha
Analysts offer different views on AbbVie as shares recoup losses ...
AbbVie (ABBV +4.4%) is up, albeit on below-average volume, as shares recoup a good chunk of Friday's bearish reversal of almost 6% from ...
PipelineReview.com (press release)
AbbVie sues Britain's NHS over HCV eradication plan
Apparent rancor over the drug procurement process has prompted AbbVie (ABBV +3.4%) to sue England's National Health Service (NHS) over ...
Seeking Alpha - 6 days ago
AbbVie (ABBV) Q3 2018 Results - Earnings Call Transcript
AbbVie, Inc. (NYSE:ABBV) Q3 2018 Earnings Call November 2, 2018 9:00 AM ET. Executives. Elizabeth Shea - AbbVie, Inc. Richard A.
Motley Fool - 1 day ago
Hagens Berman Reminds AbbVie (NYSE: ABBV) Investors of ...
SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the ...
Seeking Alpha - 29 Oct 2018
AbbVie down 4% on Humira price cut in Europe
AbbVie (ABBV -3.9%) slips on more than 60% higher volume in what would be a reasonable reaction by investors following the FDA nod for ...


Back